Oxurion NV ( (GB:0G99) ) has provided an update.
Oxurion NV announced that it received transparency notifications from Atlas Special Opportunities II LLC, indicating changes in shareholding positions. As of March 20, 2025, Atlas held 52,489 shares, crossing below the 3% threshold, and as of March 24, 2025, it held 1,007,463 shares, crossing above the 20% threshold. These changes reflect significant movements in voting securities, impacting Oxurion’s shareholder structure.
More about Oxurion NV
Oxurion is a biopharmaceutical company based in Leuven, Belgium, focused on developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease.
Technical Sentiment Signal: Strong Buy
Current Market Cap: €764.7K
For a thorough assessment of 0G99 stock, go to TipRanks’ Stock Analysis page.